Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.
Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Ozempic and similar drugs for Type 2 diabetes and weight loss are in such ... Novo Nordisk and Eli Lilly are moving to end ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
GLP-1 medications are breakthroughs for weight loss, diabetes, and more. Pharma companies are clamoring to produce pills or longer-lasting drugs with faster effects. Novo Nordisk, Eli Lilly ...